Brainstorm Cell Therapeutics (NASDAQ:BCLI) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.12), Bloomberg Earnings reports.
Brainstorm Cell Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, hitting $3.71. 229 shares of the company were exchanged, compared to its average volume of 91,868. The company has a debt-to-equity ratio of 9.34, a quick ratio of 0.97 and a current ratio of 0.97. The firm has a 50 day moving average price of $3.99. Brainstorm Cell Therapeutics has a 12-month low of $2.92 and a 12-month high of $4.50.
Several research firms have weighed in on BCLI. Maxim Group reissued a “buy” rating and set a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, May 14th. ValuEngine downgraded Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Further Reading: Certificate of Deposit (CD)
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.